Please use this identifier to cite or link to this item:
http://hdl.handle.net/10637/15397
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.other | Grupo: Spanish Back Pain Research Network (REIDE) | - |
dc.creator | García Romero, Noemí | - |
dc.creator | Palacín Aliana, Irina | - |
dc.creator | Madurga, Rodrigo | - |
dc.creator | Carrión-Navarro, Josefa | - |
dc.creator | Esteban Rubio, Susana | - |
dc.creator | Jiménez, Beatriz | - |
dc.creator | Collazo, A. | - |
dc.creator | Pérez-Rodríguez, Felipe | - |
dc.creator | Ortiz de Mendivil Arrate, Ana | - |
dc.creator | Fernández-Carballal, C. | - |
dc.creator | García-Duque, S. | - |
dc.creator | Diamantopoulos-Fernández, J. | - |
dc.creator | Belda Iniesta, Cristóbal | - |
dc.creator | Prat-Acín, R. | - |
dc.creator | Sánchez-Gómez, P. | - |
dc.creator | Calvo Aller, Emiliano | - |
dc.creator | Ayuso Sacido, Ángel | - |
dc.date.accessioned | 2024-02-08T14:19:49Z | - |
dc.date.available | 2024-02-08T14:19:49Z | - |
dc.date.issued | 2020-06-22 | - |
dc.identifier.citation | García-Romero, N., Palacín-Aliana, I., Madurga, R. et al. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. BMC Med 18, 142 (2020). https://doi.org/10.1186/s12916-020-01610-0 | es_ES |
dc.identifier.issn | 1741-7015 | - |
dc.identifier.uri | http://hdl.handle.net/10637/15397 | - |
dc.description.abstract | Background: Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods: We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. Results: We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Conclusions: Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment. | en_EN |
dc.format | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.ispartof | BMC Medicine | - |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | - |
dc.rights | OpenAccess | - |
dc.subject | VEGFA | en_EN |
dc.subject | Angiogenesis | en_EN |
dc.subject | Bevacizumab | en_EN |
dc.subject | Glioblastoma | en_EN |
dc.subject | Neovasculogenesis | en_EN |
dc.title | Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma | en_EN |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1186/s12916-020-01610-0 | - |
dc.relation.projectID | Supported by grants from the “Fondo de Investigaciones Sanitarias” (FIS) (PI17-01489), the Miguel Servet Program (CP11/00147) del Instituto de Salud Carlos III (AAS), and the Ministerio de Economía y Competitividad–FEDERER (RTC-2016-4990-1). IPA was supported by “Ayudas para la contratación de ayudantes de investigación cofinanciadas por el Fondo Social Europeo a través del Programa Operativo de Empleo Juvenil y la Iniciativa de Empleo Juvenil (YEI),” and SER was supported by FPI-CEU predoctoral fellowship. | - |
dc.centro | Universidad San Pablo-CEU | - |
Appears in Collections: | Medicina |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.